# SLS catalysts: SELLAS Life Sciences Group, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/sls/catalysts

> SELLAS Life Sciences Group, Inc. (SLS) has no upcoming catalysts in this calendar. The latest recorded is the SELLAS Life Sciences Group, Inc. earnings report, November 12, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | SELLAS Life Sciences Group, Inc. |
| Ticker | SLS (Nasdaq) |
| SEC CIK | 1390478 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/sls |

## Cash runway

Cash $134.7M as of 2026-09-30; quarterly burn $5.9M; about 68.0 months of runway at that rate (XBRL company facts, accession 0001390478-26-000020).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2023 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | SLS |  | completed, positive | "We reported positive topline safety and efficacy data from this study in June 2023 and positive follow-up immune response and survival data in December 2023." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1390478/000110465925102602/tm2529505d2_424b5.htm)) |
| Mar 2024 | [Tambiciclib topline data readout](https://sec-api.dev/pdufa/tambiciclib) | SLS |  | completed, positive | "In March 2024, we announced positive topline data from the Phase 2a clinical trial of SLS009 in combination with aza/ven in r/r/ AML." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1390478/000110465925102602/tm2529505d2_424b5.htm)) |
| Q4 2024 | [Tambiciclib interim data readout](https://sec-api.dev/pdufa/tambiciclib) | SLS | Acute Myeloid Leukemia | scheduled | "Based on a detailed analysis of all unblinded data, the IDMC projected that the interim analysis (60 events) will occur in the fourth quarter of 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/sls-202411138xkexhibit991.htm)) |
| Q4 2024 | [Tambiciclib topline data readout](https://sec-api.dev/pdufa/tambiciclib) | SLS |  | scheduled | "Additional topline data updates are expected in the fourth quarter of 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/sls-202411138xkexhibit991.htm)) |
| November 13, 2024 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/sls-202411138xkexhibit991.htm)) |
| 2025 | [Tambiciclib interim data readout](https://sec-api.dev/pdufa/tambiciclib) | SLS |  | scheduled | "-Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000004/sls-202503208xkexhibit991.htm)) |
| 2025 | [Tambiciclib topline data readout](https://sec-api.dev/pdufa/tambiciclib) | SLS |  | scheduled | ""The most anticipated milestones in 2025 will be the final analysis of our Phase 3 pivotal REGAL trial of GPS in acute myeloid leukemia (AML) and the full topline Phase 2 data of SLS009 in AML, both of which represent significant opportunities and offer hope to AML patients in need." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000004/sls-202503208xkexhibit991.htm)) |
| March 20, 2025 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000004/sls-202503208xkexhibit991.htm)) |
| May 13, 2025 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000009/sls-202505138xkexhibit991.htm)) |
| August 12, 2025 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000017/sls-202508128xkexhibit991.htm)) |
| November 12, 2025 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047825000021/sls-202511128xkexhibit991.htm)) |
| December 2025 | [Galinpepimut-s primary completion](https://sec-api.dev/pdufa/galinpepimut-s) | SLS | Acute Myeloid Leukemia | delayed | "NCT04229979 (Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12 (ESTIMATED); Lead Sponsor Sellas Life Sciences Group." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04229979)) |
| March 19, 2026 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000004/sls-202603198xkexhibit991.htm)) |
| May 12, 2026 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000009/sls-202605128xkexhibit991.htm)) |
| August 11, 2026 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/sls-202608118xkexhibit991.htm)) |
| Q4 2026 | [Tambiciclib interim data readout](https://sec-api.dev/pdufa/tambiciclib) | SLS |  | scheduled | "- 40 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Preliminary Topline Data Expected in Q4 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000021/sls-202611128xkexhibit991.htm)) |
| Q4 2026 | [Tambiciclib topline data readout](https://sec-api.dev/pdufa/tambiciclib) | SLS |  | scheduled | "- 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/sls-202608118xkexhibit991.htm)) |
| Nov 2026 | [SELLAS Life Sciences Group, Inc. interim data readout](https://sec-api.dev/companies/sls/catalysts) | SLS |  | scheduled | "Upon completion of this analysis, we expect to announce the preliminary topline primary endpoint results from the trial in accordance with the study's pre-specified statistical analysis plan in November 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000020/sls-20260930.htm)) |
| November 12, 2026 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000021/sls-202611128xkexhibit991.htm)) |

## Drugs

- [Galinpepimut-s](https://sec-api.dev/pdufa/galinpepimut-s): Acute Myeloid Leukemia
- [Tambiciclib](https://sec-api.dev/pdufa/tambiciclib): acute myeloid leukemia

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/sls/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SLS catalysts: SELLAS Life Sciences Group, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/sls/catalysts

```bibtex
@misc{secapidev_companies_sls_catalysts_20261116,
  title        = {SLS catalysts: SELLAS Life Sciences Group, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/sls/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_sls_catalysts_20261116","title":"SLS catalysts: SELLAS Life Sciences Group, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/sls/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
